EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Multiple Mononeuropathy Secondary to Parvovirus B19 Infection: A Case Series

Julian Theuriet, Maud Michaud, Guillaume Fargeot, Céline Labeyrie, Anaïs Grosset, Maude Bucy, Ludivine Kouton, Florian Hubben, Véronique Manel, Florent Cluse, Adrien Bohic, Nicolas Rodriguez, Philippe Petiot, Geneviève Billaud, Vincent Fabry, Pascal Cintas, Thierry Maisonobe, Karine Viala, Rabab Debs, Dimitri Psimaras, Sarah Leonard‐Louis, Benjamin Terrier, Alina Dorobat, Céline Tard, Stéphane Darteyre, Alex Vicino, Marie Théaudin, Clovis Adam, Françoise Bouhour, Timothée Lenglet, Grégory Destras, Nathalie Streichenberger, Antoine Pegat

European Journal of Neurology · 2026-03 · 33 (3)

DOI: 10.1111/ene.70565 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Background Parvovirus B19 (B19V) infection has been associated with neurological complications. Rarely, patients present with multiple mononeuropathy (MM). The present study aimed to better characterize the clinical, electrophysiological, and prognostic features of patients with B19V‐related MM. Methods This retrospective, observational, multicenter study included patients with B19V‐related MM diagnosed between January 2015 and January 2025 in seven university hospitals in France and Switzerland. Results Twenty‐one patients were included. Twelve were female (57%). All were immunocompetent. The median age at symptom onset was 40 years [IQR: 31–44]. All patients experienced sensory symptoms, 19 (90%) reported neuropathic pain, nine (43%) developed motor weakness, and seven (33%) had cranial nerve involvement. The most frequently involved nerves were the median (14 patients, 67%), fibular ( n = 13; 62%), and ulnar ( n = 10; 48%) nerves. B19V IgM antibodies were present in 12/20 patients (60%), and all 21 patients were positive for IgG. B19V DNA was detected in blood by PCR in 20 patients (95%). Nerve biopsy showed necrotizing small‐vessel vasculitis in one patient (17%), perivascular lymphocytic and macrophagic infiltrates in five (83%), and B19V DNA was detected by PCR in all four tested nerves. Most patients received immunomodulatory treatment ( n = 19; 90%). MM relapse occurred in four patients (19%). A partial recovery was observed in 17/20 patients (85%), two remained stable (10%), and one achieved complete recovery (5%). Conclusions B19V infection should be systematically investigated in patients presenting with MM, especially in young individuals (including children) with predominantly sensory symptoms, predominant upper limb nerve involvement, and/or cranial nerve involvement.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →